Elsevier

Kidney International

Volume 53, Issue 4, April 1998, Pages 1002-1006
Kidney International

Clinical Nephrology – Epidemiology – Clinical Trials
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy

https://doi.org/10.1111/j.1523-1755.1998.00847.xGet rights and content
Under an Elsevier user license
open archive

Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. The antiproteinuric effect of angiotensin converting enzyme (ACE) inhibition in insulin-dependent diabetes mellitus (IDDM) patients with diabetic nephropathy varies considerably. Therefore, we tested the potential role of an insertion (I)/deletion (D) polymorphism of the ACE gene on this early antiproteinuric responsiveness in an observational follow-up study. Sixty (II, N = 13; ID, N = 26 and DD, N = 21) young hypertensive IDDM patients suffering from diabetic nephropathy were investigated during three months before and for the initial six month period during ACE inhibition [captopril 44 (SD 22) mg/24 hr, no differences in drug dose between groups]. Blood pressure (MABP) and albuminuria (ELISA) were measured three (1 to 6) times before and three (1 to 13) times during ACE inhibition. At baseline the groups (II/ID/DD) had comparable (1) mean arterial blood pressure (MABP mm Hg) of 113 ± 10/108 ± 9/114 ± 8, (2) albuminuria (geometric mean with 95% CI) 1394 (747 to 2608)/1176 (844 to 1797) and 1261 (827 to 2017) mg/24 hr, and (3) serum creatinine (geometric mean with 95% CI), 80 (68 to 93)/85 (76 to 97)/103 (85 to 119) μmol/liter, respectively. Angiotensin converting enzyme inhibition induced a significant reduction in MABP, albuminuria and kidney function in all three groups (II/ID/DD; P < 0.05): (1) MABP (mean ±SD) 12 ± 7/5 ±7/8 ± 9 mm Hg (ANOVA, P = 0.02); (2) albuminuria [mean (95%CI)] 61 (34 to 77)/22 (3 to 37)/31 (13 to 46) %, (ANOVA, P < 0.01); and (3) increasing serum creatinine [mean (95%CI)] 8 (4 to 12)/9 (3 to 16)/8 (0 to 16) % (ANOVA, NS), respectively. Adjusting for differences in reduction in MABP did not change the association between decrease in albuminuria and ACE/ID genotypes (P < 0.01). A multiple linear regression analysis revealed that the ACE/ID polymorphism, albuminuria and MABP at baseline independently influenced the decline in albuminuria after initiation of ACE inhibition (R2= 0.21, P < 0.01). A significant association between changes in MABP and albuminuria was demonstrated (R2= 0.16, P < 0.01). Our data show that hypertensive albuminuric IDDM patients with the II genotype are particularly susceptible to commonly advocated renoprotective treatment.

Keywords

ACE gene and inhibition
diabetic nephropathy
IDDM
polymorphism in ACE gene
proteinuria
albuminuria
progression of diabetes
glomerular filtration rate

Cited by (0)